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Abstract
OBJECTIVES: The aim of the present paper was to conduct a comparative analysis of outcomes after thoracoscopic resection versus stand-
ard thoracotomy approach in the treatment of Pancoast tumours.
METHODS: All consecutive patients with Pancoast tumours undergoing surgical treatment from March 2000 to November 2012 were en-
rolled. Patients were divided into 2 groups according to whether a thoracoscopic or standard thoracotomy approach was adopted. In add-
ition to morbidity and mortality, (i) intensity of pain; (ii) respiratory function focusing on the postoperative value and its variation with
respect to the predicted value (Delta); (iii) analgesic consumption at different times during the postoperative course; and (iiii) survival rate
were recorded in both groups and the inter-group differences were statistically compared.
RESULTS: Of the 45 enrolled patients, 34 (75%) were included in the ﬁnal analysis (18 in the thoracoscopic group and 16 in the standard
group). Eleven (25%) patients were excluded because they (i) were unﬁt for surgery after induction therapy (n = 4); (ii) refused the operation
(n = 1) or (iii) had unexpected pleural involvement (n = 6). Compared with the standard group, in the thoracoscopic group we observed
less pain (P = 0.01), better recovery of forced vital capacity (P = 0.01) and forced expiratory value in 1 s (P < 0.001), and a reduction in
opioid (P = 0.01) and analgesic consumption (P = 0.02). The median survival for all patients was 15 months. Patients with N0/N1 disease
had better median survival than N2 patients (47 vs 9 months; P = 0.009). One local recurrence in the standard group was observed 1 year
after operation, whereas 2 local recurrences, 1 in the thoracoscopic group and another in the standard group, were registered 2 years after
the operation (P = 1.0). Finally, 4 (22%) extrathoracic metastases in the thoracoscopic group and 5 (31%) in the standard group (P = 0.8)
were found over the 2 years following the procedure.
CONCLUSIONS: In the management of Pancoast tumours, a thoracoscopic approach is safe and may be an effective adjunct to standard
surgical resection in selected cases. Such an approach enabled surgeons to explore the pleural cavity and avoid exploratory thoracotomy
in cases of unexpected pleural involvement.
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INTRODUCTION
The development of video-assisted thoracic surgery (VATS) over
the past decade has led to a signiﬁcant shift in the management of
an increasing number of thoracic pathologies, including lung
cancer resection. VATS reduced surgical trauma and maintaining
oncological principles of traditional open procedures. Recently, in
a multicentre study, Bayarri et al. [1] reported its use during open
en bloc chest-wall and pulmonary resection for locally invasive
cancer. VATS conﬁrmed chest-wall invasion when suspected on
computed tomography (CT) scan, and determined the boundaries
and location of the chest-wall involvement. It allowed placing of
the incision over the involved area, proceeding with accurate exci-
sion of the chest wall without the need for extensive thoracoto-
mies, and to proceed with pulmonary resection en bloc only
through the space available after the rib excision without the need
for rib spreading or extending of the thoracotomy [1]. Similar
results were previously obtained by the authors in the manage-
ment of Pancoast tumours [2]. The goal of this study was to review
the experience of different centres to compare VATS and standard
approaches in patients who underwent Pancoast tumour resection
during the same period, looking at all preoperative, operative and
postoperative data and prognosis.
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MATERIALS ANDMETHODS
Study design
This paper discusses a retrospective multicentre study. All con-
secutive patients with Pancoast tumours undergoing surgical
treatment as part of multimodality treatment between March
2000 and November 2012 were enrolled. Patients were divided
into 2 groups according to whether a mini-invasive approach
(VATS group) or standard thoracotomy approach (standard group)
was adopted. To make the 2 study groups reliable and comparable
and to avoid selection bias, all patients were reviewed by the
same multidisciplinary thoracic oncological team and deemed by
this team to be eligible for VATS resection. However, the decision
whether patients received a VATS or standard procedure was
based entirely on the individual surgeon’s expertise, anatomic
consideration as well as patient preference. In addition, we
excluded patients with: (i) a previous history of chronic pain; (ii) a
previous thoracic procedure; (iii) neurological disease, such as
movement limitation or cerebral confusion; and (iiii) other types
of chest-wall involvement that did not meet the criteria of the
standard deﬁnition of Pancoast tumour. The VATS group was com-
pared with the concurrent thoracotomy group in light of the fol-
lowing postoperative results: (i) intensity of pain; (ii) pulmonary
function; (iii) narcotic medication; and (iiii) survival rate. The data
were prospectively collected in a database and then retrospective-
ly compared to assess statistical inter-group differences. All
patients were informed regarding the type of operation and gave
written consent before it. Being retrospective, the study was
approved by the review board of each centre enrolled.
Patient evaluation
Between 2000 and 2012, 45 patients with Pancoast tumours eli-
gible for surgery were enrolled in the study. The patients were
observed in 3 different tertiary units of Italian thoracic surgery, in-
cluding Second University of Naples (n = 15), Hospital Cannizzaro
of Catania (n = 12) and Istituto Oncologico del Mediterraneo of
Catania (n = 18). In all centres, the diagnosis of Pancoast tumour
was made by the clinical presentation of pain around the shoulder
and upper arm, associated with a tumour in the apex of the lung.
Standard functional tests were used for assessing pulmonary
reserve; forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) were computed and calculation of predicted post-
operative (ppo) values was performed to assess surgical risk; a
ppoFEV1 of >40% was required to schedule the surgical proced-
ure. Lung carbon monoxide diffusion testing (DLCO) and quantita-
tive V/Q scan were only performed in selected cases with limited
pulmonary function [3].
In all cases, preoperative staging was performed using chest
roentgenogram and CT scan. Magnetic resonance imaging (MRI)
was used to determine tumour involvement of the vertebrae, bra-
chial plexus and subclavian vessels in patients who were candi-
dates for surgery. Positron emission tomography (18FDG-PET) has
been used since its introduction in 2000, but only became part
of the standard staging procedure and of follow-up in 2006.
Tumour diagnosis was generally obtained by CT-guided ﬁne-
needle biopsy. Invasive staging procedures were performed if
pathological lymph nodes in the mediastinum were suspected on
CT, unless PET was available and negative for mediastinal nodes.
Then, all patients were evaluated by the multidisciplinary thoracic
oncological team to assess tumour stage and decide on the treat-
ment strategy. When surgical resection was considered feasible,
the same induction therapy proposed by Southwest Oncology
Group [4] was adopted by all centres contributing to this study.
The induction chemotherapy and radiation began within 24 h of
each other. The chemotherapy regimen comprised cisplatin 50
mg/m2 on Days 1, 8, 29 and 36 and etoposide 50 mg/m2 on Days
1–5 and 29–33, both administered intravenously. Standard prehy-
dration and antiemetic medications were used. The total dose of
radiation was 45 Gy administered at 180 cGy per day, 5 days a
week, over a period of 5 weeks. The radiation target was deﬁned
by CT scan and included the primary tumour and ipsilateral supra-
clavicular region, but not the mediastinum or hilum.
Three to four weeks after the completion of radiotherapy, a re-
staging using CT and MRI was performed while invasive restaging of
the mediastinum was done if (persisting) N2 disease was suspected
on CT scan. Deﬁnitive surgery was scheduled 4–6 weeks after com-
pletion of induction treatment. After surgery, at least 2 additional
cycles of cisplatin and etoposide were planned. After completing in-
duction therapy, all centres adopted the same exclusion criteria
from surgery as follows: (i) progressive disease; (ii) persisting N2/N3
disease; (iii) (extensive) tumour invasion in neural foramina, verte-
bral bodies, brachial plexus or greater vessels; and (iv) low perform-
ance status or insufﬁcient cardiopulmonary reserve.
Surgical resection
All patients received the same regimen of anaesthesia and select-
ive intubation. The VATS procedure was as previously described
[2]. Brieﬂy, the patient was placed in the lateral decubitus position
with the arm of the operative side prepped and wrapped by
sterile waterproof stockinet so that it can be moved within the op-
erative ﬁeld. According to the VATS ﬁndings, either an anterior or
a posterior thoracotomy from 8 to 15 cm was performed without
the need to change the position of the patient intraoperatively.
After having positioned the trocars, thoracoscopic exploration of
pleural cavity was attended to evaluate potential pleural dissemin-
ation and the relation of the lung with the adjacent structures. In
cases of feasibility of surgery, resection was performed using either
a combined technique involving small posterior thoracotomy with
video-assistance support or VATS lobectomy followed by chest-wall
resection. The specimen was then removed en bloc from the pleural
cavity. Radical dissection of all mediastinal lymph nodes was rou-
tinely carried out thoracoscopically, in the standard fashion. At the
end of the procedure, 2 inter-costal drainage tubes was generally
placed in the pleural cavity and attached to underwater seals, as
shown Fig. 1. The patient was usually extubated in the operating
theatre and spent their ﬁrst 24–48 h in a thoracic surgical high-
dependency unit before moving to a thoracic surgical ward.
After the operation, all patients received standard medication
using intravenous (IV) patient control analgesia (PCA) as follows:
5 mg morphine IV bolus at ﬁrst, followed by 1.2 mg/h, which
could be maximally delivered by any patient with a 5-10-min
lockout period for the ﬁrst 48 postoperative hours (POH).
Ketorolac (administered via an intramuscular route at a dose of
15 mg every 6–8 h) was given when the patient noticed strong
pain; if the pain was uncontrollable, an additional dose of intra-
muscular administration of pentazocine (30–60 mg) was used.
Early mobilisation and aggressive pulmonary toilet was performed
in addition to physical therapy and respiratory therapy. Patients
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were educated regarding incentive spirometry preoperatively and
used it frequently postoperatively, including under direct observa-
tion. Postoperatively, they received two assisted sessions of chest
physiotherapy daily, starting on the ﬁrst postoperative day, and
were asked to repeat the physiotherapy programme 6 times
during the day until discharge. Therapeutic bronchoscopy was
instituted early, based on clinical ﬁndings and correlation with
daily chest ﬁlms. The thoracostomy tubes were usually removed
during the ﬁrst 5 or 6 postoperative days, except in cases with
complications.
Postoperative pain
Postoperative pain was measured using a visual analogue scale
(VAS) score (from 0 to 10). When asked, patients had to touch a
point corresponding to their grade of pain, and this mark indi-
cated the degree of pain on the scale. Participants completed the
VAS questionnaire before the operation and 24, 48, 72, 96, 120 h
and 1 month after the procedure.
Respiratory function
Pulmonary function tests (FVC and FEV1) were performed using
Spirolab, Spirometer (Cosmed®). The best of 3 efforts, completed
with the patient sitting on the edge of the bed, was used for
the analysis. The ppoFEV1 was calculated by using a Nakahara
formula [5]:
ppoFEV1 ¼ 1 ðn aÞð42 aÞ
 
 ppoFEV1;
where n relates to the total number of subsegments in the lobe to be
removed, whereas a relates to the number of subsegments
obstructed by the tumour. The ppoFVC was calculated in a similar
way.
The changes in the actual ppo FEV1 compared with the
ppoFEV1 (Delta FEV1) was calculated for each patient, according
to the formula:
FEV1 ratio ¼ ðactual postoperative FEV1 100Þ
ppoFEV1
:
The Delta FVC ratio was calculated similarly. The pulmonary func-
tion tests were expressed as a percent of predicted value and per-
formed 72, 96 120 h and 1 month after the operation.
Analgesic requirement
The intake of analgesic medication at different times during post-
operative course (up to Day 5 after the operation) was recorded
Figure 1: Posterior thoracotomy was performed under thoracoscopic view (A). An exploration of the pleural cavity was performed to evaluate pleural dissemination
not clinically diagnosed and the relation of the lung with adjacent structures (B). The thoracoscopic support allowed an ‘en bloc’ chest-wall resection (C) through a
small posterior thoracotomy (D).
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for both groups. Adverse effects, such as nausea, vomiting, respira-
tory depression, sedation and pruritus, were recorded and treated
with appropriate medication.
Survival
On completion of all treatment, all patients were followed up.
Patients were evaluated every 3 months during the ﬁrst 2 years
postoperatively and then every 6 months thereafter by history,
physical examination, chest radiography and blood tests. In add-
ition, scans of the brain, chest and upper part of the abdomen
were required every 6 months for the ﬁrst 3 years postoperatively,
after which they were done only if clinically indicated. Since 2006,
CT/PET has been routinely used in follow-up if requested. Survival
was measured from the ﬁrst day of chemotherapy until death
and/or loss to follow-up. Event-free survival was calculated from
the ﬁrst day of chemotherapy until any event occurred, such as
tumour progression, incidence of a second cancer, death because
of toxicity or secondary conditions, or death because of second
malignancy.
Statistical analysis
Data are presented as mean ± standard deviation (SD) or percent-
age. Differences between the 2 study groups were assessed by χ2
(qualitative data) and Mann–Whitney test (quantitative data). The
inter-group differences (VATS group vs standard group) of the
variables measured at the various postoperative time points were
achieved by repeated measures analysis of variance (ANOVA).
Survival analysis was conducted according to the Kaplan–Meier
method, and curves were compared by the log-rank test. A
P-value of <0.05 was considered statistically signiﬁcant. MedCalc®
statistical software Version 12.4.0 was used for analysis.
RESULTS
Of the 45 enrolled patients, 34 (75%) were included in the ﬁnal
analysis (18 in the VATS group and 16 in the standard group).
Eleven (25%) patients were excluded because (i) after completion
of induction chemotherapy, they had poor cardiorespiratory and
thus unﬁt for surgery (n = 4); (ii) refused operation (n = 1); or (iii)
had unexpected pleural involvement not clinically detected that
contraindicated tumour resection (n = 6). Most standard proce-
dures (75%) were performed during 2000–2010, whereas VATS
resections were performed during 2010–2012. A ﬂow chart of the
study population is depicted in Fig. 2.
Characteristics of patients
The characteristics of two groups are summarised in Table 1.
There were no signiﬁcant differences regarding preoperative data:
age, sex, comorbidities, respiratory function, tumour side, clinical
stage and histology. At presentation, 31/34 tumours (91%) inﬁl-
trated only the bony and soft tissue structures of the upper thoracic
inlet and, thus, were classiﬁed as cT3 (17 in the VATS group and 14
in the standard group). In the remaining 3 cases (9%), an
Figure 2: Flow chart of study population.
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involvement of the vertebral bodies (cT4) was also detected (1 in
the VATS group and 2 in the standard group). All but 1 patient in
the standard group completed the planned induction therapy
without treatment-related death. At restaging, a partial response
was seen in 16 and 13 patients of VATS and standard groups, re-
spectively (P = 0.8), whereas no signiﬁcant change in tumour
volume was seen in 2 and 3 patients from the VATS and standard
groups, respectively (P = 0.8). No case of distant metastases was
found.
In the standard group, the surgical approaches were 11 postero-
lateral thoracotomy, 4 combined posterior thoracotomy and 1
transmanubrial L-shaped incision. Thoracotomy ranged from 30
to 40 cm and latissimus dorsi muscle was always resected. In the
VATS group, 16 posterior thoracotomies, 1 combined posterior
thoracotomy and 1 transmanubrial L-shaped incision were done.
The incision ranged from 8 to 15 cm; no conversion to a wider
thoracotomy was attended and latissimus dorsi muscle was always
preserved. In only 5 cases (3 of the VATS group and 2 of the
Table 1: Characteristics of the study population
Variables VATS group (n = 18) Standard group (n = 16) P-value
Age 62.5 (range 39–76) 68 (range 48–78) 0.7
Male 14 (78%) 13 (81%) 0.8
Smoke 15 (83%) 14 (87%) 0.8
Mean body mass index 28 ± 4.5 31 ± 7.5 0.7
COPD 4 (22%) 4 (25%) 0.8
Cardiac 7 (38%) 7 (43%) 0.9
Diabetes 2 (11%) 3 (18%) 0.8
Tumour side
Right 15 (83%) 11 (69%) 0.5
Left 3 (17%) 5 (31%) 0.5
Diagnosis
Adenocarcinoma 11 (61%) 10 (62.5%) 0.9
Others 7 (39%) 6 (37.5%) 0.7
Clinical stage
IIB-T3N0M0 8 (44%) 7 (44%) 1.0
IIIA 9 (50%) 7 (44%) 0.7
T3N1M0 1 0
T3N2M0 8 7
IIIB 1 (6%) 2 (12%) 0.9
T4N0M0 0 0
T4N2M0 1 2
Induction therapy
Radiotherapy alone – –
Chemotherapy alone – 1 0.9
Chemotherapy + radiotherapy 18 (100%) 15 (94%) 0.9
Response to induction therapy
Partial 16 (89%) 13 (81%) 0.8
None 2 (11%) 3 (19%) 0.8
Approach
Posterior 16 (89%) 11 (69%) 0.5
Anterior 1 (5.5%) 1 (6%) 0.5
Combined 1 (5.5%) 4 (25%) 0.2
Type of resection
Lobectomy 15 (83%) 14 (88%) 0.7
Wedge 3 (17%) 2 (12%) 0.7
Operative data
Operation time 227 ± 25 230 ± 37 0.7
Intraoperative blood loss 291 ± 31 375 ± 75 0.0004
Blood transfusion 1 (5%) 5 (31%) 0.1
Pathological stage
IIB- T3N0M0 10 (55%) 5 (31%) 0.2
IIIA 7 (39%) 9 (62%) 0.5
T3N1M0 2 1
T3N2M0 5 8
IIIB 1 (6%) 2 (12%) 0.9
T4N0M0 0 1
T4N2M0 1 1
Postoperative complications
Respiratory failure 4 (22%) 3 (18%) 0.8
Atelectasis requiring aspiration 2 (11%) 4 (25%) 0.5
Cardiac – 2 (12%) 0.4
Others 1 (5.5%) 0 0.9
Chest drain duration (days) 4.7 ± 0.7 5.1 ± 1.7 0.2
Length of hospital stay (days) 7.7 ± 1.5 8.5 ± 1.2 0.6
COPD: chronic obstructive pulmonary disease; VATS: video-assisted thoracic surgery.
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standard group), a nonanatomical resection was performed for a
respiratory condition. En bloc chest-wall resection and mediastinal
lymph adenectomy were always performed. The mean number of
resected ribs was 2.9 ± 0.6 in the VATS group vs 3.0 ± 0.7 in the
standard group (P = 0.6). Among the standard group, in addition
to chest-wall resection and lobectomy, a partial vertebrectomy
(D2 and D3) with spinal stabilisation was performed in 1 patient
and in another a vertebral processes resection of D1–D4 was
achieved. Among the VATS group, a vertebral processes resection
of D1 and D2, in addition to chest-wall resection of three ribs and
lobectomy, was performed. An R0 resection was achieved in all
patients except 2 among the standard group (R1). The mean op-
erative time of the VATS group was similar to that of the standard
group (227 ± 25 vs 230 ± 37; P = 0.7); a signiﬁcant reduction in
intraoperative blood loss was observed in the VATS group com-
pared with the standard group (291 ± 31 vs 375 ± 75; P = 0.0004),
but no signiﬁcant difference was found among the two groups
regarding blood transfusion, chest drain duration and length of
hospital stay. No operative death or reinterventions were regis-
tered. Respiratory failure was observed in 4 (22%) and 3 (18%)
patients from the VATS and standard groups, respectively, without
signiﬁcant difference (P = 0.8). However, patients from the stand-
ard group required more bronchoscopic aspiration compared
with those from the VATS group. In the standard group, 2 patients
presented with postoperative atrial ﬁbrillation, whereas 1 patient
from the VATS group had a liquoral ﬁstula treated intraoperatively.
Visual analogue scale
The data are summarised in Fig. 3. No signiﬁcant difference was
seen between the VATS and standard groups before operation
(6.5 ± 1.2 vs 6.7 ± 1.1). The mean pain score of the VATS group was
lower with respect to the standard group at 24 POHs (5.5 ± 0.9 vs
5.7 ± 0.7), 48 POHs (4.8 ± 0.6 vs 5.2 ± 0.5), 72 POHs (4 ± 0.4 vs
4.5 ± 0.6), 96 POHs (3.6 ± 0.4 vs 4 ± 0.5), 120 POHs (3.6 ± 0.5 vs
3.8 ± 0.5) and 1 month after the procedure (2.5 ± 0.8 vs 3.1 ± 0.9).
The difference in VAS score between the two study groups was
statistically signiﬁcant (P = 0.006).
Respiratory function
The results are summarised in Table 2. Between the VATS and
standard groups, similar preoperative values of FVC (85% ± 5.6 vs
89% ± 4.9; P = 0.7) and FEV1 (88% ± 3.4 vs 86% ± 6.3; P = 0.8) were
seen. The ANOVA test showed better values of FVC (P = 0.01;
Fig. 4A) and FEV1 (P < 0.001; Fig. 4B) in the VATS group compared
with the standard group. Yet, the comparison of Delta FEV1 and
Delta FVC between the groups showed that the loss of FVC
(P = 0.009; Fig. 4C) and FEV1 (P = 0.01; Fig. 4D) was signiﬁcantly
less in the VATS group than in the standard group.
Analgesic requirement
Morphine requirement was lower in the VATS group compared
with the standard group on postoperative day 1 (23.3 mg ± 4.8 vs
26.8 mg ± 4.1) and postoperative day 2 (17.7 mg ± 4.7 vs 21.7 mg
Figure 3: The VAS pain score of the VATS group was signiﬁcantly lower than that
of the standard group during the entire postoperative course (P = 0.006;
ANOVA test). VAS, visual analogue scale.
Table 2: Functional data of study population
Variable Group Baseline value 72 POHs 96 POHs 120 POHs 1 POM P-value
FVC (%) VATS 85 ± 5.6 61 ± 4.8 64 ± 4.3 69 ± 5.6 72 ± 5.9 0.01
Standard 89 ± 4.9 58 ± 5.4 63 ± 3.7 65 ± 3.8 67 ± 4.7
FEV1 (%) VATS 88 ± 3.4 64 ± 4.5 67 ± 0.9 72 ± 6 72 ± 4.9 <0.001
Standard 86 ± 6.3 60 ± 5 64 ± 3.6 68 ± 3.9 67 ± 3.5
ppoFEV1 (%)
Delta FVC VATS 74.5 ± 4.5 −9.6 ± 5.3 −7.1 ± 3.6 −2.5 ± 3.8 −1.4 ± 1.8 0.009
Standard 72 ± 2.3 −12 ± 4.5 −9 ± 3.4 −5.8 ± 2.8 −4.1 ± 2.7
Delta FEV1 VATS 74.1 ± 3.7 −8.6 ± 6 −6.2 ± 4 −2.1 ± 3.6 −1.3 ± 0.3 0.01
Standard 72.5 ± 2.1 −11 ± 3.9 −9 ± 3.3 −5.1 ± 2.8 −3.6 ± 0.4
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; VATS: video-assisted thoracic surgery; POHs: postoperative hours; POM: postoperative month;
ppo: predictive postoperative.
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± 4.3). The difference between the 2 study groups was statistically
signiﬁcant with a P-value of 0.01. After 48 POHs, only 1 patient in
the standard group required a supplementary dose of morphine.
Compared with the standard group, the VATS group showed a re-
duction in Ketorolac consumption on postoperative day 1 (10.6
mg ± 7.5 vs 15 mg ± 7.7); 2 (9.3 mg ± 5.7 vs 12.1 mg ± 5.9); 3 (11.2
mg ± 6.1 vs 13.1 mg ± 6.5); 4 (7.7 mg ± 5 vs 13 mg ± 5.1); and 5
(3.3 mg ± 2.3 mg vs 9.6 ± 3.1). The repeated measures ANOVA in
the two study groups showed a P-value of 0.02.
Survival
The median survival for all patients was 15 months. The 3-year
survival rate was 31% (n = 7), the 5-year survival rate was 16%
(n = 4) and the 10-year survival rate was 5% (n = 1) (Fig. 5A).
We analysed the effect of the extent of the disease on survival
as reﬂected by the The TNM staging system. Regarding the
tumour extension, only 3/34 (9%) patients had a classiﬁcation of
T4, with a median survival of 13 months. Two of these patients
had an R1 resection and presented with a local recurrence 5 and
13 months after the procedure, respectively. Another T4 patient
with a R0 resection presented with a local recurrence 14 months
following the procedure. Of the patients with lymph node involve-
ment, 19/34 (56%) had N0 or N1 disease, and 15/34 (46%) had N2
mediastinal involvement. N0 or N1 were combined as N0 for
survival analysis, because of the small number of N1 cases (n = 2).
The median survival of patients with N0/N1 disease was 47 vs 9
months for N2 patients, with a signiﬁcant difference [hazard ratio:
2.5; 95% conﬁdence interval (CI): 1.07–6.02; P = 0.009] (Fig. 5B).
Distant metastasis was observed in 32% of patients (11/34),
whereas local recurrence occurred in 12% (4/34). However, con-
sidering the shorter follow-up of the VATS group compared with
that of the standard group, we evaluated only the 1-year and
2-year recurrence when comparing the two groups (Table 3). Only
1 local recurrence in the standard group was observed 1 year
after the operation, whereas 2 local recurrences, 1 in the VATS and
another in the standard group, were registered 2 years after the
operation (P = 1.0). Finally, 9/34 (26%) extrathoracic metastases
were found for 2 years following the procedure: 4 (22%) in the
VATS group (2 brain, 1 liver and 1 bone metastases) and 5 (31%) in
the standard group (3 brain, 1 bone and 1 kidney metastases) with
no signiﬁcant difference (P = 0.8).
DISCUSSION
Surgical treatment of Pancoast tumour is a challenging procedure
because of the invasion of adjacent structures, such as brachial
plexus, subclavian vessels and spine. Over the years, different strat-
egies have been proposed. The surgical standard approach is a
radical en bloc resection through extended posterolateral
Figure 4: In the VATS group, better values of FVC (P = 0.01; A) and FEV1 (P < 0.001; B) were seen compared with the standard group. Yet, the comparison of Delta
FEV1 and Delta FVC between the groups showed that the loss of FVC (P = 0.009; C) and FEV1 (P = 0.01; D) was signiﬁcantly less in the VATS group than in the standard
group. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; VATS: video-assisted thoracic surgery.
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thoracotomy as described by Shaw et al. [6]. With tumours invad-
ing the anterior aspects of the ﬁrst rib or subclavian artery or vein,
an anterior approach is helpful. A new anterior approach was pro-
posed by Dartevelle et al. [7] using an anterior cervicothoracic ap-
proach with an L-shaped incision paralleling the anterior border
of the sternocleidomastoid muscle down the midline to the level
of the second or third ribs, extending laterally to the deltopectoral
groove. The medial clavicle is resected. Grunenwald and Spaggiari
[8] then described a clavicle-sparing modiﬁcation of the anterior
approach involving detachment and elevation of the clavicle with
an attached portion of sternum to gain access to the ﬁrst rib and
thoracic inlet. The disadvantage of such a technique is the asso-
ciated morbidity because the operation must be completed with
posterolateral thoracotomy to perform the upper lobe lobectomy.
The use of VATS in the treatment of Pancoast tumours has been
reported in sporadic case reports or small case series. Vallières
et al. [9] ﬁrst reported the possible use of thoracoscopy for the
staging and assessment of Pancoast tumour candidates for
surgery. Other authors [10 11 12 13] reported the resection of
Pancoast tumours through the transmanubrial approach of
Grunenwald and Spaggiari [8] combined with VATS lobectomy.
Recently, we published our positive experience in the treatment
of a consecutive series of 10 patients with Pancoast tumours
undergoing resection using the VATS approach. It is well known
that VATS versus standard lobectomy reduces pain and surgical
trauma, and results in less bleeding, earlier functional recovery
and a shorter hospital stay with associated cost savings [14].
However, until now, no study has evaluated whether such data
can be extrapolated to the treatment of Pancoast tumours.
The results of our study supported the general idea that the
VATS approach causes less pain and reduces morbidity in
Pancoast surgery. In fact, the VATS group had a lower VAS score
compared with the standard group at each time point during the
postoperative course and 1 month after the procedure. It is well
known that thoracotomy incisions are prone to the development
of acute and chronic postoperative pain because of the possibility
of direct inter-costal nerve and rib injury from the spreading of
the interspace by the thoracic retraction. Given that, in both
groups, a chest-wall resection was performed with direct nerve
injury and rib fracture, other factors should be taken into account
to explain our results.
Whereas the length of skin incision in the VATS group was gen-
erally 8–15 cm, that of the standard group was 30–40 cm. Thus,
we believe that this comparatively big difference in incision length
between the two approaches caused signiﬁcant differences in
chest pain and pulmonary function. Additional crucial factors
resulting in a lower level of postoperative pain in the VATS group
include the reduced rib spreading and the preservation of latissi-
mus dorsi that was always resected in the standard group. The div-
ision of the bulky lateral thoracic musculature following
thoracotomy is a well-known factor associated with increasing
postoperative pain and signiﬁcant acute and chronic disability.
Nomori et al. [15] reported that pain scores between 1 week and 6
months after surgery were signiﬁcantly lower after anterior limit-
ing thoracotomy than after a standard posterolateral procedure
and that VATS resulted in a further lowering of the pain score for 1
week following surgery [16]. In theory, such evidence may be
more evident in the management of Pancoast tumours that
require larger incisions compared with other types of resection, i.
e. lobectomy alone.
The clinical implication of less pain observed in the VATS group
helped the earlier recovery of pulmonary function compared with
the standard group. The decline in spirometric results was more
evident in the standard than in the VATS group. In the VATS group,
FVC and FEV1 results decreased from 85 and 88% (preoperative
results) to 61 and 64% (at 72 POHs), respectively, whereas in the
standard group, FEV1 and FVC results decreased from 88 and 86%
(preoperative results) to 58 and 60% (at 72 POHs), respectively.
During the subsequent postoperative hours up to the ﬁrst month
after the procedure, FVC and FEV1 increased progressively in both
groups but the improvement was more evident in the VATS than
Figure 5: The median survival for all patients was 15 months. The 3-year sur-
vival rate was 31%, the 5-year survival rate was 16% and the 10-year survival
rate was 5% (A); the median survival of patients with N0/N1 disease was 47
months vs 9 months of N2 patients with a signiﬁcant difference (hazard ratio:
2.5; 95% conﬁdence interval: 1.07–6.02; P = 0.009; B).
Table 3: Recurrence of study population
Recurrence VATS group (n = 18) Standard group (n = 16) P-value
1 year
Local – 1 (6%)
Distant – – 0.9
2 years
Local 1 1 1.0
Distant 4 (22%) 5 (31%) 0.8
VATS: video-assisted thoracic surgery.
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in the standard group. Although the two groups were well
matched, the respiratory function percentage after resection may
be affected by several factors, including the size of wedge resec-
tion, the laterality of upper lobectomy and the size of the tumour
that had occupied the upper lobe, rather than because of the sur-
gical approach alone. Thus, we also evaluated the changes in post-
operative respiratory functions between the 2 groups with respect
to ppo values and found that that the loss of FVC (P = 0.004) and
of FEV1 (P = 0.01) was signiﬁcantly less in the VATS group than in
the standard group. Pulmonary function has been reported to
remain unchanged or even improve after lobectomy in patients
with chronic obstructive pulmonary disease (COPD). However, the
percentage of patients with COPD is similarly low in both groups
and, thus, the VATS approach was the principal driver of respira-
tory beneﬁt observed in the VATS group. The better impact of
VATS compared with standard approach on respiratory function
especially in patients with poor respiratory function undergoing
lung resection has been recently reported in several papers. Berry
et al. [17] and Kachare et al. [18] found that a low preoperative pul-
monary function was a signiﬁcant risk factor for respiratory com-
plications in patients undergoing open lung resection but not in
patients who received thoracoscopic resection. Traibi et al. [19]
found fewer complications in thoracoscopy groups undergoing
segmentectomy with poor FEV1, whereas more than half of these
patients in the thoracotomy group had a complication. A recent
review concluded that patients in whom pulmonary function was
poor had perioperative outcomes similar to the outcomes of
those with normal pulmonary function when a VATS approach to
resection was adopted [20]. In theory, the surgical trauma resulting
from traditional thoracotomy prevents the most aggressive
physiotherapy and the most cooperation for achieving optimum
respiratory care. The depression of respiratory function represents
an inability to breathe deeply and cough effectively. This leads
to signiﬁcant alveolar collapse, severe hypoxemia and gross post-
operative pulmonary complications [21]. Conversely, the lower
trauma resulting from the VATS approach would enable the same
patients to tolerate more vigorous physiotherapy and to generate
spontaneously more effective cough during the postoperative
period, as well as to ambulate in a more liberal manner. In theory,
this may explain why patients from the standard group required
signiﬁcantly more frequent bronchoscopic aspiration than the
VATS group. The lower pain level of the VATS group also explained
the signiﬁcant difference between the 2 groups in terms of opioid
intake over the ﬁrst 48 POHs and the analgesic intake following
surgery.
The median survival of the entire study population was 28
months. The 3-year survival was 45% and 5-year survival was 27%,
which is similar to the historical value of 30% reported in the lit-
erature [4]. T4 disease (n = 3) and incomplete resection (n = 2)
were adverse prognostic factors with a median survival of 13
months. Although it does not represent a contraindication to sur-
gical resection, Detterbeck et al. [22] emphasised that subclavian
artery involvement and vertebral body invasion (3 patients from
our study groups) were two major negative prognostic factors.
Also, the presence of N2 disease was correlated with poor prog-
nosis compared with N0/N1 disease in agreement with other
reports. In our series, distant recurrence was the most frequent
form of primary relapse with high frequency in the brain; this
raises the complex question proposed by other authors of
whether patients who have a better prognosis (i.e. major or com-
plete pathological response and complete resection) should be
offered prophylactic cranial radiation [4]. However, despite the
short follow-up (2 years), no signiﬁcant difference was found
between the VATS and standard procedure groups. Only 1 local
recurrence in the standard group was observed 1 year after oper-
ation, whereas 2 local recurrences, 1 in the VATS and another in
the standard group, were registered 2 years after the operation
(P = 1.0). In addition, distant metastases were observed in 4 and 5
patients from the VATS and standard groups, respectively (P = 0.8).
Given that the dimension of the tumor (T status) and the lymph
node involvement (N status) were similar between the two
groups, this support the impression that VATS presented a similar
oncological efﬁcacy compared with the standard technique for re-
section of Pancoast tumour, as reported previously in other
studies that compared VATS versus thoracotomy lobectomy. In the
resection of Pancoast tumours, the possibility of having an R0 re-
section using a VATS approach similar to thoracotomy but with
the advantage of lower mortality and morbidity is corroborated
by other single-case series. In addition, another merit of the VATS
approach is the possibility of evaluating the pleural cavity and
avoiding extramorbidity caused by exploratory thoracotomy in
cases of unexpected pleural involvement not seen by radiological
evaluation [23]. In our study population, 6 patients presented at
surgery with a pleural carcinosis not clinically diagnosed and, in 4
cases, exploratory thoracotomy was avoided using VATS.
Finally, proceeding with the VATS approach may reduce post-
operative discomfort as reported above, but when inappropriately
used, it may result in minimally effective results. Thus, it should be
performed by experienced thoracic surgeons who have proper
insight into the pathological thoracic process and the expected
outcomes from the thoracic surgical intervention.
Study limitations
We are well aware of the limitations of the study: (i) because it was
a multicentre study, different surgeons performed surgical resec-
tion with inevitable differences; (ii) although no signiﬁcant differ-
ences were seen between the two groups regarding preoperative
and postoperative data, the retrospectively nature of the study did
not permit random assignment to treatment; (iii) although all
patients were eligible for VATS resection, the decision to perform
VATS or standard resection may be affected by the surgeon’s con-
ﬁdence with the VATS approach; and (iv) the postoperative data
were collected by different investigators.
CONCLUSIONS
In the management of Pancoast tumour, our study seemed to
conﬁrm the well-known advantages of VATS versus open lobec-
tomy. In fact, in selected cases, the thoracoscopic approach offers
a good overview of the superior sulcus, which is helpful in deter-
mining the level of thoracic wall resection and avoiding extramor-
bidity caused by a larger thoracotomy. Another advantage of VATS
is the possibility of exploring the pleural cavity and avoiding ex-
ploratory thoracotomy in cases of unexpected pleural involve-
ment. However, our data should be corroborated by larger and
randomised studies because of the retrospective nature of our
study and the small number and the short follow-up of patients
enrolled.
F.P. Caronia et al. / Interactive CardioVascular and Thoracic Surgery434
ACKNOWLEDGEMENTS
We thank Alain Bisson and Vincenzo Pastore for their invaluable
opinions and encouragement in the completion of this study.
Conﬂict of interest: none declared.
REFERENCES
[1] Bayarri CI, de Guevara AC, Martin-Ucar AE. Initial single-port thoraco-
scopy to reduce surgical trauma during open en bloc chest wall and pul-
monary resection for locally invasive cancer. Interact CardioVasc Thorac
Surg 2013;17:32–5.
[2] Caronia FP, Rufﬁni E, Lo Monte AI. The use of video-assisted thoracic
surgery in the management of Pancoast tumors. Interact CardioVasc
Thorac Surg 2010;11:721–6.
[3] Santini M, Fiorello A, Vicidomini G, Di Crescenzo VG, Laperuta P. Role of
diffusing capacity in predicting complications after lung resection for
cancer. Thorac Cardiovasc Surg 2007;55:391–4.
[4] Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T et al.
Induction chemoradiation and surgical resection for superior sulcus
non-small-cell lung carcinomas: long-term results of Southwest Oncology
Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007;25:313–8.
[5] Nakahara K, Monden Y, Ohno K, Miyoshi S, Maeda H, Kawashima Y. A
method for predicting postoperative lung function and its relation to post-
operative complications in patients with lung cancer. Ann Thorac Surg
1985;39:260–5.
[6] Shaw RR. Pancoast’s tumor. Ann Thorac Surg 1984;37:343–5.
[7] Dartevelle PG, Chapelier AR, Macchiarini P, Lenot B, Cerrina J, Ladurie FL
et al. Anterior transcervical-thoracic approach for radical resection of lung
tumors invading the thoracic inlet. J Thorac Cardiovasc Surg 1993;105:
1025–34.
[8] Grunenwald D, Spaggiari L. Transmanubrial osteomuscular sparing ap-
proach for apical chest tumors. Ann Thorac Surg 1997;63:563–6.
[9] Vallières E, Karmy-Jones R, Mulligan MS, Wood DE. Pancoast tumors. Curr
Probl Surg 2001;38:306–76.
[10] Nakajima T, Watanabe A, Nakazawa J, Higami T. Transmanubrial approach
with video-assisted thoracoscopic surgery for left superior sulcus tumor
with dens adhesion after replacement of descending aorta. Interact
CardioVasc Thorac Surg 2012;14:906–8.
[11] Truin W, Siebenga J, Belgers E, Bollen EC. The role of video-assisted thor-
acic surgery in the surgical treatment of superios sulcus tumor. Interact
CardioVasc Thorac Surg 2010;11:512–4.
[12] Linden PA. Video-assisted anterior approach to Pancoast tumors. J Thorac
Cardiovasc Surg 2010;140:e38–9.
[13] Shikuma K, Miyahara R, Osako T. Transmanubrial approach combined
with video-assisted approach for superior sulcus tumor. Ann Thorac Surg
2012;94:e29–30.
[14] Marty-Ané CH, Canaud L, Solovei L, Alric P, Berthet JP. Video-assisted
thoracoscopic lobectomy: an unavoidable trend? A retrospective single-
institution series of 410 cases. Interact CardioVasc Thorac Surg 2013;17:
36–43.
[15] Nomori H, Horio H, Suemasu K. Anterior limited thoracotomy with
intrathoracic illumination for lung cancer: its advantages over anteroaxil-
lary and posterolateral thoracotomy. Chest 1999;115:874–80.
[16] Jensen K, Petersen RH, Hansen HJ. Video assisted thoracic surgery lobec-
tomy: review of data strongly suggests the interest of its further implemen-
tation. EJCMO 2011;3:26–34.
[17] Berry M, Villamizar-Ortiz N, Tong B, Burfeind W, Harpole D, D’Amico T
et al. Pulmonary function tests do not predict pulmonary
complications after thoracoscopic lobectomy. Ann Thorac Surg 2010;89:
1044–52.
[18] Kachare S, Dexter E, Nwogu C, Demmy T, Yendmuri S. Perioperative out-
comes of thoracoscopic anatomic resections in patients with limited pul-
monary reserve. J Thorac Cardiovasc Surg 2011;141:459–62.
[19] Traibi A, Grigoroiu M, Boulitrop C, Urena A, Masuet-Aumatell C, Brian E
et al. Predictive factors for complications of anatomical pulmonary seg-
mentectomies. Interact CardioVasc Thorac Surg 2013;17:838–44.
[20] Oparka J, Yan TD, Ryan E, Dunning J. Does video-assisted thoracic surgery
provide a safe alternative to conventional techniques in patients with
limited pulmonary function who are otherwise suitable for lung resection?
Interact CardioVasc Thorac Surg 2013;17:159–62.
[21] Fiorelli A, Morgillo F, Milione R, Pace MC, Passavanti MB, Laperuta P et al.
Control of post-thoracotomy pain by transcutaneous electrical nerve
stimulation: effect on serum cytokine levels, visual analogue scale,
pulmonary function and medication. Eur J Cardiothorac Surg 2012;41:
861–8.
[22] Detterbeck FC, Jones DR, Kernstine KH, Naunheim KS; American College
of Physicians. Lung cancer. Special treatment issues. Chest 2003;123:
244–58.
[23] Fiorelli A, Santini M. In lung cancer patients where a malignant pleural ef-
fusion is found at operation could resection ever still be justiﬁed? Interact
CardioVasc Thorac Surg 2013;17:407–12.
O
R
IG
IN
A
L
A
R
TI
C
LE
F.P. Caronia et al. / Interactive CardioVascular and Thoracic Surgery 435
